Clinical trial
Ozanimod (Zeposia®) In Patients With RRMS: A 3-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)
NCT05335031 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ozanimod (Zeposia®) In Patients With RRMS: A 3-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 3, 2021
- Completion date
- June 30, 2025
- Enrollment
- 450 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.